IP Verse

Ipsen competitive analysis

Latest oppositions filed by Ipsen

Explore patent oppositions filed by Ipsen against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 3, 2026
Patent NumberTitleApplicantOpposition Date
EP4161562
High Dose And Low Volume Botulinum Toxin Treatment Of Facial WrinklesMERZ PHARMAAug 20, 2025
EP3368071
Injectable Botulinum Toxin Formulations And Methods Of Use Thereof Having Long Duration Of Therapeutic Or Cosmetic EffectREVANCE THERAPEUTICSOct 26, 2022
EP3432916
Stabilized Non-Protein Clostridial Toxin CompositionsALLERGANMay 12, 2020
EP3436054
Stabilized Non-Protein Clostridial Toxin CompositionsALLERGANMay 12, 2020
EP3094331
Combination-Based Treatment MethodNEKTAR THERAPEUTICSSep 27, 2018
EP2692350
Lyophilized Preparation Of Botulinum ToxinMEDY TOXFeb 2, 2018
EP1543329
Cell-Based Fluorescence Resonance Energy Transfer (Fret) Assays For Clostridial ToxinsALLERGANMay 3, 2017
EP2373294
Clostridial Toxin Pharmaceutical CompositionsALLERGANJan 18, 2017
EP2679217
Non-Protein Stabilized Clostridial Toxin Pharmaceutical CompositionsALLERGANJan 5, 2017
EP2085093
Preparation Containing Highly Purified Botulinum Toxin Type A Derived From Infant Botulism PathogenJURIDICAL FOUNDATIONNov 24, 2015

Latest patents of Ipsen opposed by its competitors

Explore Ipsen's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 3, 2026
Patent NumberPublication DateTitleTotal Oppositions
EP3362049
Jul 9, 2025Stabilizing Camptothecin Pharmaceutical Compositions2
EP3796929
Sep 18, 2024Suppression Of Bone Cancer-Induced Allodynia1
EP3758611
Jul 24, 2024Use Of Ultrasound To Guide Injection Of Non-Cytotoxic Protease1
EP1817051
Apr 10, 2024Pharmaceutical Compositions Comprising Botulinum Neurotoxin, A Non Ionic Surfactant, Sodium Chloride And Sucrose3
EP3266456
May 5, 2021Combinations Of Liposomal Irinotecan, 5-Fu And Leucovorin For The Treatment Of Pancreatic Cancer3
EP3337467
Dec 9, 2020Combination Therapy Using Liposomal Irinotecan And A Parp Inhibitor For Cancer Treatment1
EP3337478
Aug 12, 2020Methods For Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan And Oxaliplatin2
EP2664343
Dec 18, 2019Suppression Of Cancer1
EP2939688
Feb 20, 2019Pharmaceutical Compositions Comprising Botulinum Neurotoxin1
EP2398495
Jul 11, 2018Modified Non-Cytotoxic Proteases1

Latest PTAB cases involving Ipsen

Discover the latest PTAB cases involving Ipsen, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 6, 2026
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Ipsen

IPR2025-01531Sep 12, 2025APOTEXIPSEN BIOPHARMFinal Written Decision
IPR2025-00505Jan 17, 2025CSPC PHARMACEUTICAL GROUPIPSEN BIOPHARMFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Ipsen with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 3, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
IPSEN - 5 - -
ALLERGAN16431333
DAEWOONG PHARMACEUTICAL1 - - -
IVA SCHMETZ GMBH1 - - -